BridgeBio Pharma BBIO Reportable Segment — Total Costs & Expenses

Similar metrics at other companies

SMMTReportable Segment — Operating Expenses

$195.21M+192%

BIIBReportable Segment — Other segment expense

$317M-10.4%

OMCReportable Segment — Costs and Expenses

$5.5B+71.6%

MEDPReportable Segment — Costs and Expenses

$565.1M+27.0%

ELANReportable Segment — Costs and Expenses

$574M+19.6%

BIIBReportable Segment — SG&A

$608.4M+1.2%

Questions, answered.

What is BridgeBio Pharma's reportable segment — total costs & expenses?

BridgeBio Pharma (BBIO) reported reportable segment — total costs & expenses of $300.47M in Q1 2026.

How has BridgeBio Pharma's reportable segment — total costs & expenses changed year-over-year?

BridgeBio Pharma's reportable segment — total costs & expenses increased by 36.0% year-over-year, from $221.01M to $300.47M.

What does reportable segment — total costs & expenses mean?

The total operating expenditure for the segment.

How do you interpret reportable segment — total costs & expenses?

An increase indicates higher operational scale or rising costs, which must be balanced against revenue growth.

How does reportable segment — total costs & expenses compare across companies?

Standard total operating expense reporting.